Document is current
Any future updates will be listed below
-
Authors
Zorigtbaatar, Anudari https://orcid.org/0000-0002-5050-8967
Li, Zhihao
Magyar, Christian T. J. https://orcid.org/0000-0002-4570-949X
Aceituno, Laia https://orcid.org/0000-0001-5414-2408
Saborowski, Anna https://orcid.org/0000-0003-4857-4276
Vogel, Arndt https://orcid.org/0000-0003-0560-5538
Grant, Robert C.
O’Kane, Grainne M. https://orcid.org/0000-0002-8690-403X
Sapisochin, Gonzalo
- License Information
-
More Information
Article History
Accepted: 6 February 2026
First Online: 3 March 2026
Competing interests
: A.S. has acted as an adviser of Bristol Myers Squibb (BMS), Eisai, Incyte, Jazz Pharmaceuticals, MSD, Roche and Taiho, has received honoraria from Amgen, AstraZeneca, BMS, Eisai, Ipsen, Lilly, MSD, Roche and Servier, has received travel support from Eisai, Ipsen, MSD, Pierre-Fabre and Servier, and has served on the advisory boards of, and is a member of the Data and Safety Monitoring Board of Heparegenix. A.V. has acted as a consultant and/or adviser and has received honoraria from AstraZeneca, BeiGene, BMS, Boehringer Mannheim, BTG, EISAI, GSK, Incyte, Ipsen, Merck Sharpe & Dohme, Roche, Servier, Sirtex and Taiho. G.M.O.’K. has acted as a consultant and/or adviser of AstraZeneca, Roche, Servier and Zymeworks, has acted as a speaker on behalf of Merck Sharpe & Dohme, has received research grants from AstraZeneca and Roche, and has received travel support from Merck Sharpe & Dohme, Novartis, Roche and Takeda. G.S. has acted as a consultant of AstraZeneca, HepaRegeniX, Integra, Novartis and Roche, has acted as a speaker on behalf of AstraZeneca, Chiesi, Integra and Roche, has received research funding from Roche, has research collaborations with AstraZeneca, HeparegeniX, Natera, Roche and Stryker, and holds stock in Amgen, CVS Health, Gilead, Johnson & Johnson, Merck Sharpe & Dohme, Pfizer and UnitedHealth. All other authors declare no competing interests.
